Jochem van Werkum

Showing 1-5 of 5 articles

Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay

Heestermans A, de Boer M, van Werkum J, Mosterd A, Gosselink A, Dambrink J, van Houwelingen K, Koopmans P, Hamm C, Zijlstra F, ten Berg J, van’t Hof A

August 30, 2011 | 10.4244/EIJV7I4A73

Triggering mechanisms of stent thrombosis

Zwart B, van Werkum J, Heestermans A, Kelder J, Zomer A, van’t Hof A, Verheugt F, ten Berg J

January 20, 2011

Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial

Timmer J, ten Berg J, Heestermans A, Dill T, van Werkum J, Dambrink J, Suryapranata H, Ottervanger J, Hamm C, van’t Hof A

August 15, 2010

Platelet reactivity as a risk-factor for stent thrombosis: can this be one of the currently available appropriate methods to determine platelet reactivity?

van Werkum J, ten Berg J

August 20, 2008

Point-of-care platelet function testing in patients undergoing PCI: is it ready for use in clinical practice?

ten Berg J, van Werkum J

August 20, 2008

1

Latest news

Focus on emerging physiology indices, TAVI, sizing with abnormal aortic cusps, a megaregistry of complex PCIs and more…

Tetralogy of Fallot with acquired double right ventricular outflow tract

September 18, 2020

Ahead of print: Leaflex Study

September 23, 2020

Integrating physiology in OCT

September 23, 2020

BioFlow IV, TWILIGHT, Evolut Low Risk and many others

(Released thanks to the support of Biotronik)

September 25, 2020

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Steady-state hyperaemia

September 18, 2020

This Week's JAA's: Biograde Study, Advances in valvular heart interventions...

September 22, 2020

Valvular disease